What does Samsung Biologics’ new $262m Songdo manufacturing deal signal?
Samsung Biologics adds a $262 million manufacturing deal through 2033 as its capacity, acquisitions and global CDMO ambitions expand.
Pharma & Biotech
Pharma & Biotech
Samsung Biologics is buying more than GLP-1 capacity in its CHF 1.46bn PolyPeptide bet
Samsung Biologics’ CHF 1.46 billion PolyPeptide bid adds GLP-1 capacity and six global sites. Read why integration will decide its real long-term payoff.